脓毒症生物标志物的研究进展

曾茁; 彭毅志; 袁志强

doi:10.3760/cma.j.cn501225-20230320-00086

脓毒症生物标志物的研究进展

doi: 10.3760/cma.j.cn501225-20230320-00086

陆军军医大学（第三军医大学）第一附属医院，全军烧伤研究所，创伤、烧伤与复合伤　国家重点实验室，重庆　　400038

基金项目:

国家自然科学基金面上项目 82072171, 81873935

详细信息

通讯作者:
彭毅志，Email：yizhipen@sina.com

计量
- 文章访问数: 476
- HTML全文浏览量: 120
- PDF下载量: 74
- 被引次数: 0
出版历程
- 收稿日期: 2023-03-20
- 网络出版日期: 2023-07-19

Research advances of sepsis biomarkers

State Key Laboratory of Trauma, Burns and Combined Injury, Institute of Burn Research, the First Affiliated Hospital of Army Medical University (the Third Military Medical University), Chongqing 400038, China

Funds:

General Program of National Natural Science Foundation of China 82072171, 81873935

More Information

Corresponding author: Peng Yizhi, Email: yizhipen@sina.com

摘要

摘要: 脓毒症是危及患者生命的疾病。生物标志物可用于对脓毒症的诊断、治疗和预后评估。近年来不断有新的脓毒症生物标志物被发现，迄今已确定的生物标志物超过250种。脓毒症发生过程的复杂性以及各种检测技术灵敏度的提高将会导致新的生物标志物不断涌现。但针对脓毒症，目前临床上仍缺乏特异性的用于诊断的生物标志物以及有效的治疗方法。因此，寻找可靠的生物标志物以及评估生物标志物在脓毒症中的运用无疑有助于指导临床决策。该文综述了脓毒症生物标志物的研究现状，以期加强对目前脓毒症生物标志物的认识，为生物标志物运用于脓毒症的诊断、治疗和预后评估提供参考。
- 脓毒症 /
- 诊断 /
- 预后 /
- 生物标志物
Abstract: Sepsis is a life-threatening condition for patients. Biomarkers can be used for the diagnosis, treatment, and prognostic assessment of sepsis. In recent years, new biomarkers for sepsis have been discovered, and more than 250 biomarkers have been identified so far. The complexity of the sepsis process and the increased sensitivity of various detection techniques will lead to the emergence of new biomarkers. However, there is still a lack of specific diagnostic biomarkers and effective therapeutic approaches for sepsis in clinical practice. Therefore, the search for reliable biomarkers and the evaluation of the role of biomarkers in sepsis will undoubtedly aid in clinical decision-making. This article reviews the advances on research of sepsis biomarkers in order to improve understanding of current biomarkers of sepsis, and provide reference for the application of biomarkers in clinical diagnosis, treatment, and prognosis of sepsis.
- Sepsis /
- Diagnosis /
- Prognosis /
- Biomarker
所有作者均声明不存在利益冲突

HTML全文

参考文献(46)

[1]	ZhangP, ZouB, LiouYC, et al. The pathogenesis and diagnosis of sepsis post burn injury[J/OL]. Burns Trauma, 2021,9:tkaa047[2023-03-20]. https://pubmed.ncbi.nlm.nih.gov/33654698/. DOI: 10.1093/burnst/tkaa047.
[2]	RuddKE, JohnsonSC, AgesaKM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study[J]. Lancet, 2020,395(10219):200-211. DOI: 10.1016/S0140-6736(19)32989-7.
[3]	PierrakosC, VincentJL. Sepsis biomarkers: a review[J]. Crit Care, 2010,14(1):R15. DOI: 10.1186/cc8872.
[4]	SinhaM, JupeJ, MackH, et al. Emerging technologies for molecular diagnosis of sepsis[J]. Clin Microbiol Rev, 2018,31(2) :e00089-17. DOI: 10.1128/CMR.00089-17.
[5]	LippiG. Sepsis biomarkers: past, present and future[J]. Clin Chem Lab Med, 2019,57(9):1281-1283. DOI: 10.1515/cclm-2018-1347.
[6]	Van WyngeneL, VandewalleJ, LibertC. Reprogramming of basic metabolic pathways in microbial sepsis: therapeutic targets at last?[J]. EMBO Mol Med, 2018,10(8):e8712. DOI: 10.15252/emmm.201708712.
[7]	Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework[J]. Clin Pharmacol Ther, 2001, 69(3):89-95. DOI: 10.1067/mcp.2001.113989.
[8]	PierrakosC, VelissarisD, BisdorffM, et al. Biomarkers of sepsis: time for a reappraisal[J]. Crit Care, 2020,24(1):287. DOI: 10.1186/s13054-020-02993-5.
[9]	LiS, RongH, GuoQ, et al. Serum procalcitonin levels distinguish Gram-negative bacterial sepsis from Gram-positive bacterial and fungal sepsis[J]. J Res Med Sci, 2016,21:39. DOI: 10.4103/1735-1995.183996.
[10]	TanJ, LiN, GongY, et al. Procalcitonin kinetics early after severe burn injury and its value in diagnosis of sepsis[J]. Burns, 2021,47(8):1802-1809. DOI: 10.1016/j.burns.2021.02.024.
[11]	KahnF, TverringJ, MellhammarL, et al. Heparin-binding protein as a prognostic biomarker of sepsis and disease severity at the emergency department[J]. Shock, 2019,52(6):e135-e145. DOI: 10.1097/SHK.0000000000001332.
[12]	KleinHJ, NiggemannP, BuehlerPK, et al. Pancreatic stone protein predicts sepsis in severely burned patients irrespective of trauma severity: a monocentric observational study[J]. Ann Surg, 2021,274(6):e1179-e1186. DOI: 10.1097/SLA.0000000000003784.
[13]	YuMH, ChenMH, HanF, et al. Prognostic value of the biomarkers serum amyloid A and nitric oxide in patients with sepsis[J]. Int Immunopharmacol, 2018,62:287-292. DOI: 10.1016/j.intimp.2018.07.024.
[14]	DoganyigitZ, ErogluE, AkyuzE. Inflammatory mediators of cytokines and chemokines in sepsis: from bench to bedside[J]. Hum Exp Toxicol, 2022,41:9603271221078871. DOI: 10.1177/09603271221078871.
[15]	LiuG, JiangC, LinX, et al. Point-of-care detection of cytokines in cytokine storm management and beyond: significance and challenges[J]. View (Beijing), 2021,2(4):20210003. DOI: 10.1002/VIW.20210003.
[16]	KangS, KishimotoT. Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms[J]. Exp Mol Med, 2021,53(7):1116-1123. DOI: 10.1038/s12276-021-00649-0.
[17]	LingH, ChenM, DaiJ, et al. Evaluation of qSOFA combined with inflammatory mediators for diagnosing sepsis and predicting mortality among emergency department[J]. Clin Chim Acta, 2023,544:117352. DOI: 10.1016/j.cca.2023.117352.
[18]	YuB, ChenM, ZhangY, et al. Diagnostic and prognostic value of interleukin-6 in emergency department sepsis patients[J]. Infect Drug Resist, 2022,15:5557-5566. DOI: 10.2147/IDR.S384351.
[19]	KarakikeE, AdamiME, LadaM, et al. Late peaks of HMGB1 and sepsis outcome: evidence for synergy with chronic inflammatory disorders[J]. Shock, 2019,52(3):334-339. DOI: 10.1097/SHK.0000000000001265.
[20]	Beltrán-GarcíaJ, ManclúsJJ, García-LópezEM, et al. Comparative analysis of chromatin-delivered biomarkers in the monitoring of sepsis and septic shock: a pilot study[J]. Int J Mol Sci, 2021,22(18):9935. DOI: 10.3390/ijms22189935.
[21]	TextorisJ, GordonAC. Sepsis: who will shoot first? Pharma or diagnostics?[J]. Intensive Care Med, 2018,44(8):1331-1333. DOI: 10.1007/s00134-018-5234-5.
[22]	BlotM, ZeggayA, Aho-GleleLS, et al. Is blood lymphocyte count a prognostic biomarker in Staphylococcus aureus bacteremia?[J]. J Investig Med, 2022, 70(7):1549-1552. DOI: 10.1136/jim-2022-002356.
[23]	ZhaoPY, YaoRQ, ZhengLY, et al. Nuclear fragile X mental retardation-interacting protein 1-mediated ribophagy protects T lymphocytes against apoptosis in sepsis[J/OL]. Burns Trauma, 2023,11:tkac055[2023-03-20]. https://pubmed.ncbi.nlm.nih.gov/36873287/. DOI: 10.1093/burnst/tkac055.
[24]	LiuB, DuH, ZhangJ, et al. Developing a new sepsis screening tool based on lymphocyte count, international normalized ratio and procalcitonin (LIP score)[J]. Sci Rep, 2022,12(1):20002. DOI: 10.1038/s41598-022-16744-9.
[25]	WuHP, ChuangLP, LiuPH, et al. Decreased monocyte HLA-DR expression in patients with sepsis and acute kidney injury[J]. Medicina (Kaunas), 2022,58(9):1198. DOI: 10.3390/medicina58091198.
[26]	XuJ, LiJ, XiaoK, et al. Dynamic changes in human HLA-DRA gene expression and Th cell subsets in sepsis: Indications of immunosuppression and associated outcomes[J]. Scand J Immunol, 2020,91(1):e12813. DOI: 10.1111/sji.12813.
[27]	LeijteGP, RimmeléT, KoxM, et al. Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes[J]. Crit Care, 2020,24(1):110. DOI: 10.1186/s13054-020-2830-x.
[28]	LiuQ, LiCS. Programmed cell death-1/programmed death-ligand 1 pathway: a new target for sepsis[J]. Chin Med J (Engl), 2017,130(8):986-992. DOI: 10.4103/0366-6999.204113.
[29]	ZhangT, Yu-JingL, MaT. Role of regulation of PD-1 and PD-L1 expression in sepsis[J]. Front Immunol, 2023,14:1029438. DOI: 10.3389/fimmu.2023.1029438.
[30]	ZhaoY, JiaY, LiC, et al. Predictive value of soluble programmed death-1 for severe sepsis and septic shock during the first week in an intensive care unit[J]. Shock, 2019,51(3):289-297. DOI: 10.1097/SHK.0000000000001171.
[31]	WilsonJK, ZhaoY, SingerM, et al. Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study[J]. Crit Care, 2018,22(1):95. DOI: 10.1186/s13054-018-2020-2.
[32]	JiangW, LiX, DingH, et al. PD-1 in Tregs predicts the survival in sepsis patients using sepsis-3 criteria: a prospective, two-stage study[J]. Int Immunopharmacol, 2020,89(Pt A):107175. DOI: 10.1016/j.intimp.2020.107175.
[33]	LiuM, ZhangX, ChenH, et al. Serum sPD-L1, upregulated in sepsis, may reflect disease severity and clinical outcomes in septic patients[J]. Scand J Immunol, 2017,85(1):66-72. DOI: 10.1111/sji.12509.
[34]	BakhshianiZ, FouladiS, MohammadzadehS, et al. Correlation of sPD1 with procalcitonin and C-reactive protein levels in patients with sepsis[J]. Cell J, 2021,23(1):14-20. DOI: 10.22074/cellj.2021.6941.
[35]	Andaluz-OjedaD, NguyenHB, Meunier-BeillardN, et al. Superior accuracy of mid-regional proadrenomedullin for mortality prediction in sepsis with varying levels of illness severity[J]. Ann Intensive Care, 2017,7(1):15. DOI: 10.1186/s13613-017-0238-9.
[36]	HsiaoSY, KungCT, TsaiNW, et al. Concentration and value of endocan on outcome in adult patients after severe sepsis[J]. Clin Chim Acta, 2018,483:275-280. DOI: 10.1016/j.cca.2018.05.007.
[37]	HoshinoK, KitamuraT, NakamuraY, et al. Usefulness of plasminogen activator inhibitor-1 as a predictive marker of mortality in sepsis[J]. J Intensive Care, 2017,5:42. DOI: 10.1186/s40560-017-0238-8.
[38]	ZhouW, RaoH, DingQ, et al. Soluble CD14 subtype in peripheral blood is a biomarker for early diagnosis of sepsis[J]. Lab Med, 2020,51(6):614-619. DOI: 10.1093/labmed/lmaa015.
[39]	QinQ, LiangL, XiaY. Diagnostic and prognostic predictive values of circulating sTREM-1 in sepsis: a meta-analysis[J]. Infect Genet Evol, 2021,96:105074. DOI: 10.1016/j.meegid.2021.105074.
[40]	SunB, GuoS. miR-486-5p serves as a diagnostic biomarker for sepsis and its predictive value for clinical outcomes[J]. J Inflamm Res, 2021,14:3687-3695. DOI: 10.2147/JIR.S323433.
[41]	WangR, ZhaoJ, WeiQ, et al. Potential of circulating lncRNA CASC2 as a biomarker in reflecting the inflammatory cytokines, multi-organ dysfunction, disease severity, and mortality in sepsis patients[J]. J Clin Lab Anal, 2022,36(8):e24569. DOI: 10.1002/jcla.24569.
[42]	HausfaterP, Robert BoterN, Morales IndianoC, et al. Monocyte distribution width (MDW) performance as an early sepsis indicator in the emergency department: comparison with CRP and procalcitonin in a multicenter international European prospective study[J]. Crit Care, 2021,25(1):227. DOI: 10.1186/s13054-021-03622-5.
[43]	VellyL, VolantS, FittingC, et al. Optimal combination of early biomarkers for infection and sepsis diagnosis in the emergency department: the BIPS study[J]. J Infect, 2021,82(4):11-21. DOI: 10.1016/j.jinf.2021.02.019.
[44]	SongJ, MoonS, ParkDW, et al. Biomarker combination and SOFA score for the prediction of mortality in sepsis and septic shock: a prospective observational study according to the Sepsis-3 definitions[J]. Medicine (Baltimore), 2020,99(22):e20495. DOI: 10.1097/MD.0000000000020495.
[45]	LiuJ, BaiC, LiB, et al. Mortality prediction using a novel combination of biomarkers in the first day of sepsis in intensive care units[J]. Sci Rep, 2021,11(1):1275. DOI: 10.1038/s41598-020-79843-5.
[46]	LinM, ZhangL, TangX, et al. The value of neutrophil/lymphocyte ratio combined with red blood cell distribution width in evaluating the prognosis of emergency patients with sepsis[J]. Emerg Med Int, 2022, 2022:1673572. DOI: 10.1155/2022/1673572.